Research statistics
ATX-304 research: publications and trials
At a glance
Publications, all years
14
Since 2018
Publications in 2026 so far
1
Through November 15, 2026
Human clinical research
7.1%
1 of 14 classified
Registered clinical trials
0
ClinicalTrials.gov
Randomized controlled trials
0
Publications reporting an RCT in people
Systematic reviews and meta-analyses
0
Preclinical studies
92.9%
13 animal · 0 in vitro · 0 computational
Records that only mention it
2
Not counted above
Status in the library: In clinical trials. Groups: Longevity and mitochondrial peptides.
What to keep in mind
- Fewer than three randomized controlled trials are indexed.
- More than 70% of the indexed publications are animal, cell or computational studies.
- Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
- Not a peptide: it is shown for completeness and left out of every peptide total.
Publications by year
ATX-304 publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Total |
|---|---|---|---|
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 2 | 2 |
| 2025 | 0 | 2 | 2 |
| 2026 (to date) | 0 | 1 | 1 |
Study types
| Animal study | 13 |
|---|---|
| Other clinical trial | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 5 |
|---|---|
| Cardiovascular | 4 |
| Neurological and mental health | 4 |
| Endocrinology | 3 |
| Musculoskeletal | 3 |
| Longevity and aging | 2 |
| Cognitive health | 1 |
| Gastrointestinal | 1 |
| Obesity and weight management | 1 |
| Reproductive and sexual health | 1 |
| Tissue repair | 1 |
Registered clinical trials
A registration is not a result.
No registered trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients.
JCI insight · June 21, 2018 · Other clinical trial · cited 108 times · open access
PMID 29925691 · DOI 10.1172/jci.insight.99114 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients.
JCI insight · June 21, 2018 · Other clinical trial · cited 108 times · open access
PMID 29925691 · DOI 10.1172/jci.insight.99114 · Human clinical research
- NTRK1 knockdown induces mouse cognitive impairment and hippocampal neuronal damage through mitophagy suppression via inactivating the AMPK/ULK1/FUNDC1 pathway.
Cell death discovery · October 31, 2023 · Animal study · cited 41 times · open access
PMID 37907480 · DOI 10.1038/s41420-023-01685-7 · Animal studies
- AMPK activator O304 improves metabolic and cardiac function, and exercise capacity in aged mice.
Communications biology · November 18, 2021 · Animal study · cited 27 times · open access
PMID 34795407 · DOI 10.1038/s42003-021-02837-0 · Animal studies
- AMPK Activator O304 Protects Against Kidney Aging Through Promoting Energy Metabolism and Autophagy.
Frontiers in pharmacology · March 2, 2022 · Animal study · cited 23 times · open access
PMID 35308246 · DOI 10.3389/fphar.2022.836496 · Animal studies
- Antihyperalgesia effect of AMP-activated protein kinase (AMPK) activators in a mouse model of postoperative pain.
Regional anesthesia and pain medicine · June 21, 2019 · Animal study · cited 15 times · open access
PMID 31229963 · DOI 10.1136/rapm-2019-100651 · Animal studies
Latest publications
- Ginkgolide B mitigates doxorubicin-induced cardiotoxicity by regulating AMPK-mediated mitochondrial fission via P-Drp1/OPA1 and apoptosis.
Archives of biochemistry and biophysics · August 20, 2026 · Animal study · cited 0 times
PMID 42624274 · DOI 10.1016/j.abb.2026.110979 · Animal studies
- O304 is a mitochondrial uncoupler which extends C. elegans lifespan and induces vasorelaxation of rat mesenteric arteries.
Chemico-biological interactions · October 21, 2025 · Animal study · cited 2 times
PMID 41130350 · DOI 10.1016/j.cbi.2025.111788 · Animal studies
- AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching.
JCI insight · April 8, 2025 · Animal study · cited 12 times · open access
PMID 40197369 · DOI 10.1172/jci.insight.179990 · Animal studies
- O304 alleviates abdominal aortic aneurysm formation via AMPK/mTOR/MMP pathway activation.
Frontiers in pharmacology · November 29, 2024 · Animal study · cited 7 times · open access
PMID 39679375 · DOI 10.3389/fphar.2024.1457817 · Animal studies
- The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · May 14, 2024 · Animal study · cited 9 times · open access
PMID 38749175 · DOI 10.1016/j.biopha.2024.116730 · Animal studies
- NTRK1 knockdown induces mouse cognitive impairment and hippocampal neuronal damage through mitophagy suppression via inactivating the AMPK/ULK1/FUNDC1 pathway.
Cell death discovery · October 31, 2023 · Animal study · cited 41 times · open access
PMID 37907480 · DOI 10.1038/s41420-023-01685-7 · Animal studies
- O304 ameliorates hyperglycemia in mice by dually promoting muscle glucose effectiveness and preserving β-cell function.
Communications biology · August 25, 2023 · Animal study · cited 8 times · open access
PMID 37626210 · DOI 10.1038/s42003-023-05255-6 · Animal studies
- Analgesic Effectiveness and Dorsal Root Ganglia Protein Modulation of a Peripheral Adenosine Monophosphate Kinase Alpha Activator (O304) Following Lumbar Disk Puncture in the Mouse.
Anesthesia and analgesia · October 6, 2022 · Animal study · cited 2 times
PMID 36201356 · DOI 10.1213/ane.0000000000006228 · Animal studies
- AMPK Activator O304 Protects Against Kidney Aging Through Promoting Energy Metabolism and Autophagy.
Frontiers in pharmacology · March 2, 2022 · Animal study · cited 23 times · open access
PMID 35308246 · DOI 10.3389/fphar.2022.836496 · Animal studies
- Pan-AMPK activator O304 prevents gene expression changes and remobilisation of histone marks in islets of diet-induced obese mice.
Scientific reports · December 23, 2021 · Animal study · cited 12 times · open access
PMID 34949756 · DOI 10.1038/s41598-021-03567-3 · Animal studies
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: ATX-304; O304
((TITLE_ABS:"ATX-304" OR CHEM:"ATX-304" OR TITLE_ABS:"ATX304" OR CHEM:"ATX304") OR (TITLE_ABS:"O304" OR CHEM:"O304" OR TITLE_ABS:"O 304" OR CHEM:"O 304")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). ATX-304 research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/atx-304